Regeneron Pharmaceuticals (REGN) Status update summary

Strategic Overview and Program Flexibility

• The C5 program leverages siRNA (cemdisiran) and antibody (pozelimab) to tailor complement inhibition intensity to disease biology, enabling optimal efficacy and safety across multiple indications.

• Cemdisiran reduces C5 production in the liver, while pozelimab neutralizes residual circulating C5, allowing for complete pathway blockade when needed.

• Flexibility allows for monotherapy or combination approaches, matching treatment to disease requirements in PNH, gMG, and Geographic Atrophy.

• Partial C5 inhibition is sufficient for gMG, while complete inhibition is necessary for PNH; the approach is being explored for optimal use in Geographic Atrophy.

• Regeneron holds global rights to cemdisiran as monotherapy and in combination, with all revenues recorded and modest royalties/milestones to Alnylam.

Clinical Development, Validation, and Efficacy Data

• In PNH, cemdisiran plus pozelimab achieved superior disease control and LDH normalization compared to ravulizumab, with 96% of patients maintaining hemolysis control.

• In gMG, cemdisiran monotherapy met all primary and key secondary endpoints in Phase 3 NIMBLE, delivering rapid, deep, and durable efficacy with quarterly dosing and a favorable safety profile.

• Cemdisiran showed lower rates of adverse events and no serious infections or treatment discontinuations in gMG trials; infection rates were lower with cemdisiran (27%) than placebo (40%).

• At week 24 in gMG, cemdisiran showed a 2.3-point placebo-adjusted improvement in MG-ADL and a 2.8-point improvement in QMG scores, both statistically significant.

• Systemic C5 inhibition in Geographic Atrophy aims to reduce treatment burden and ocular safety risks, with phase III data expected in late 2026.

Commercial Strategy, Outlook, and Market Opportunity

• The C5 franchise targets multi-billion-dollar opportunities in gMG, PNH, and GA, with combined markets currently generating ~$9 billion annually and significant growth expected.

• Cemdisiran is positioned for a differentiated launch in gMG, leveraging quarterly subcutaneous dosing and strong efficacy to compete in a rapidly expanding advanced therapy market.

• Commercialization is indication-specific, optimizing value and access, with plans for international expansion and a focus on self-administration to further reduce treatment burden.

• U.S. gMG market expected to more than double by 2032, driven by advanced therapies and increased treatment rates.

• Commercial launches expected in gMG (Q4 2026), PNH (2028), and GA (2029+), creating long-term growth opportunities.